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Abstract
Background: Several studies have shown that darbepoetin alfa, an erythropoiesis-stimulating
agent (ESA), can reduce transfusions and increase hemoglobin (Hb) levels in patients with
chemotherapy-induced anemia (CIA). Recent safety concerns, however, have prompted changes to
ESA product information. In the European Union and United States, ESA therapy initiation for CIA
is now recommended at a Hb level ≤10 g/dL. The present exploratory analysis examined how ESA
initiation at this Hb level may impact patient care.
Methods: Data from a phase 3 randomized trial were retrospectively reanalyzed. CIA patients
with nonmyeloid malignancies were randomized 1:1 to 500 mcg darbepoetin alfa every three weeks
(Q3W) or 2.25 mcg/kg darbepoetin alfa weekly (QW) for 15 weeks. A previously published report
from this trial showed Q3W dosing was non-inferior to QW dosing for reducing transfusions from
week 5 to end-of-the-treatment period (EOTP). In the present analysis, outcomes were reanalyzed
by baseline Hb <10 g/dL and ≥10 g/dL. Endpoints included transfusion rates, Hb outcomes, and
safety profiles.
Results: This study reanalyzed 351 and 354 patients who initiated ESA therapy at a baseline Hb of
<10 g/dL or ≥10 g/dL, respectively. From week 5 to EOTP, the estimated Kaplan-Meier transfusion
incidence (Q3W vs QW) was lower in the ≥10 g/dL baseline-Hb group (14% vs 21%) compared
with the <10 g/dL baseline-Hb group (36% vs 41%). By week 5, the ≥10 g/dL baseline-Hb group,
Published: 3 September 2009
BMC Cancer 2009, 9:311 doi:10.1186/1471-2407-9-311
Received: 25 February 2009
Accepted: 3 September 2009
This article is available from: http://www.biomedcentral.com/1471-2407/9/311
© 2009 Vansteenkiste et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cancer 2009, 9:311 http://www.biomedcentral.com/1471-2407/9/311
Page 2 of 12
(page number not for citation purposes)
but not the <10 g/dL baseline-Hb group, achieved a mean Hb ≥11 g/dL. The Kaplan-Meier estimate
of percentage of patients (Q3W vs QW) who achieved Hb ≥11 g/dL from week 1 to EOTP was
90% vs 85% in the ≥10 g/dL baseline-Hb group and 54% vs 57% in the <10 g/dL baseline-Hb group.
Both baseline-Hb groups maintained mean Hb levels <12 g/dL and had similar safety profiles, though
more patients in the ≥10 g/dL baseline-Hb group reached the threshold Hb of ≥13 g/dL.
Conclusion: In this exploratory analysis, darbepoetin alfa Q3W and QW raised Hb levels and
maintained mean Hb at <12 g/dL in both baseline-Hb groups. The ≥10 g/dL baseline-Hb group had
fewer transfusions and faster anemia correction. Additional studies should prospectively evaluate
the relationship between Hb levels at ESA initiation and outcomes.
Trial Registration: ClinicalTrials.gov Identifier NCT00118638.
Background
Patients with cancer who receive myelosuppressive chem-
otherapy may develop chemotherapy-induced anemia
(CIA), which can be a debilitating condition resulting in
increased morbidities and fatigue [1,2]. Erythropoiesis-
stimulating agents (ESAs) are recombinant therapeutic
agents (such as darbepoetin alfa and Epoetin alfa) that are
used to treat anemia. Another method used to treat ane-
mia is red blood cell (RBC) transfusions, which have only
a transient effect and are associated with risks, such as
exposure to infectious agents [3] and the more common
risk of transfusion-related acute lung injury [4]. In addi-
tion, a retrospective cohort study recently observed that
transfusions were associated with an increased incidence
of thromboembolic events and increased mortality in
hospitalized cancer patients [5]. There are also safety con-
cerns with ESAs, including the established increased risk
of venous thromboembolic events [6]. However, ESAs are
currently the only therapeutic alternative to transfusions.
Numerous clinical trials have demonstrated the efficacy of
ESAs for reducing the incidence of transfusions and rais-
ing hemoglobin (Hb) levels in cancer patients receiving
chemotherapy [7-12]. Some studies have also indicated
that ESAs can reduce fatigue in this patient population
[2,10,13,14], as recognized by evidence-based guidelines
[15]. ESAs are currently approved in both the European
Union (EU) and the United States (US) for treating ane-
mia in cancer patients receiving myelosuppressive chemo-
therapy [16-19].
Though ESAs appear to have an established efficacy pro-
file and favorable adverse-event profile in adult cancer
patients, recent findings from several individual studies
conducted in off-label ESA settings have raised concerns
regarding the potential for ESA-associated adverse survival
and disease progression outcomes [8,20-26]. Information
from eight individual studies reporting increased mortal-
ity and/or disease progression with ESA use have been
added globally to all ESA product information [16-19].
Although 4 of these 8 studies were conducted in the
approved chemotherapy setting, 3 of the 4 were anemia-
prevention studies that allowed inclusion of patients with
high baseline Hb levels [20,22,25] and all 4 studies tar-
geted high Hb values (≥12 g/dL) [8,20,22,25]. The 4 stud-
ies not conducted in the chemotherapy setting were
performed in off-label settings, such as patients not receiv-
ing chemotherapy or radiotherapy (ie, anemia of cancer
[AoC]) [24,26] and patients receiving radiotherapy only
[21,23].
In addition to describing information from these studies,
the EU product information for all ESAs [16,17] also
states that 1) ESA therapy should be initiated at a Hb level
≤10 g/dL, 2) the Hb target range should be 10 to 12 g/dL,
and 3) a sustained Hb level > 12 g/dL attained with ESA
use should be avoided. The US ESA product information
[18,19] recommends that ESAs 1) not be used in the AoC
or radiotherapy alone settings, 2) are not indicated for the
treatment of anemia in the chemotherapy setting when
the anticipated outcome is cancer cure, 3) be initiated in
patients with Hb levels < 10 g/dL, and 4) be used to main-
tain the lowest Hb level sufficient to avoid transfusions.
Meta-analyses have been performed to examine the body
of evidence available from controlled ESA studies per-
formed in cancer patients. Fifty-nine randomized control-
led ESA trials that reported mortality, conducted in both
on-label and off-label ESA settings, were identified in a lit-
erature search conducted for a 2008 meeting between the
Oncologic Drugs Advisory Committee to the Food and
Drug Administration (FDA) and the companies that mar-
ket ESAs in the US (Amgen Inc. and Centocor Ortho Bio-
tech, which is a subsidiary of Johnson & Johnson) [27].
The meta-analysis of these data, along with three addi-
tional large meta-analyses, reported point estimates for
mortality for which the confidence interval included 1
(95% confidence intervals [CI]: 0.99-1.18 [6], 0.90-1.45
[14], 0.95-1.12 [27], 0.98-1.18 [28]). Recently, two large
meta-analyses (including a patient-level meta-analysis by
the Cochrane Collaboration) of ESA use in all oncology
settings reported 95% confidence intervals for mortalityBMC Cancer 2009, 9:311 http://www.biomedcentral.com/1471-2407/9/311
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risk where the lower limit was equal to or slightly above 1
(95% CI: 1.00-1.12 [29],1.01-1.20 [30]). However, in the
Cochrane Collaboration meta-analysis, the 95% confi-
dence interval of the overall survival hazard ratio observed
in 38 controlled ESA studies in the chemotherapy setting
with 10,441 cancer patients overlapped 1 (1.04, 95% CI:
0.97 to 1.11) [29]. Unlike the previous 2006 Cochrane
meta-analysis by Bohlius et al (2006) [6], this more recent
meta-analysis from the Cochrane Collaboration also
examined on-study deaths in the same set of 38 chemo-
therapy trials (hazard ratio = 1.10; 95% CI: 0.98 to 1.24)
[29].
Because of the new environment surrounding ESA use in
oncology and because varying results have been reported
in meta-analyses of ESA oncology trials, additional trial
data are needed to inform treatment decisions. Here we
present an exploratory analysis examining hematological
outcomes in CIA patients treated with darbepoetin alfa
who were categorized in two baseline-Hb strata of < 10 g/
dL or ≥10 g/dL. The purpose of this analysis was to pro-
vide insight into how changes in the approved ESA recom-
mendations regarding the Hb level at which to initiate
ESA therapy may impact patient care. The data for this
analysis came from a pivotal, phase 3, double-blind, dou-
ble-dummy, randomized, active-controlled darbepoetin
alfa trial in CIA patients. This trial was chosen because it
was a large randomized study that compared every-three-
week (Q3W) and weekly (QW) darbepoetin alfa dosing
schedules, which are the two schedules listed in the darbe-
poetin alfa product information [13,18]. Results previ-
ously published from this trial by Canon et al (2006) [11]
indicated that 500 mcg Q3W darbepoetin alfa was non-
inferior to 2.25 mcg/kg QW darbepoetin alfa in reducing
the transfusion incidence from week 5 to end of the treat-
ment period (EOTP) (the trial's primary endpoint) [11].
The Q3W and QW treatment arms also produced similar
results for the secondary endpoints, which included the
percentage of patients achieving a target Hb ≥11 g/dL
from week 5 to EOTP, the change in Hb levels from base-
line to EOTP, and safety outcomes [11]. In the present
exploratory analysis from this trial, patients were analyzed
according to baseline-Hb category (< 10 g/dL vs ≥10 g/
dL); outcomes examined included the effect of Q3W or
QW darbepoetin alfa on transfusion rates, Hb levels, and
safety endpoints.
Methods
Patients and study design
The patient-eligibility criteria and study design for this
phase 3, randomized, double-blind, active-controlled,
double-dummy study are described in the primary report
by Canon et al (2006) [11]. This trial was conducted in
accordance with the Helsinki Declaration (ClinicalTri-
als.gov Identifier NCT00118638). An ethics committee
approved the protocol at each study center, and patients
provided informed consent before initiation of study pro-
cedures. Eligible patients (≥18 years of age) with CIA (Hb
level < 11 g/dL within 24 hours prior to randomization),
non-myeloid malignancy, at least 12 weeks of planned
cytotoxic chemotherapy, and an Eastern Cooperative
Oncology Group performance status of 0 to 2 were rand-
omized 1:1 to receive 15 weeks of a fixed dose of 500 mcg
Q3W darbepoetin alfa or a weight-based dose of 2.25
mcg/kg QW darbepoetin alfa [11]. Randomization was
stratified by tumor type (lung or gynecologic vs others),
screening Hb concentration (< 10 g/dL vs ≥10 g/dL), and
European region (Western vs Central and Eastern). The
dose of blinded study drug was withheld if a patient's Hb
level was > 13 g/dL; after Hb levels decreased to ≤12 g/dL,
study drug was reinstated at 60% of the previous dose. If
Hb levels increased by ≥1 g/dL over a 14-day period (in
the absence of a RBC transfusion during the previous 14
days), the dose of study drug was decreased to 60% of that
used previously. Any additional dose reductions pro-
ceeded in 40% dose decrements. Transfusions were rec-
ommended, but not mandated, for patients with a Hb
concentration ≤8 g/dL or > 8 g/dL with symptoms of ane-
mia. All randomized patients who received at least one
dose of study drug and remained in the study until at least
day 29 were included in the analyses. Safety endpoints
were evaluated according to treatment actually received in
patients who received at least one dose of study drug.
The primary endpoint of the trial [11] was to examine if
Q3W darbepoetin alfa was non-inferior to QW darbepoe-
tin alfa for reducing transfusions from week 5 to EOTP
(defined as the earlier of day 109 or end of study). This
time period was chosen as ESA effects are often not appar-
ent until the second month of ESA treatment [10]. This
time period has been accepted by regulatory agencies as
sufficient for drug approval. However, as some patients
respond before that timeframe, a sensitivity analysis was
also performed of transfusion incidence from week 1 to
EOTP. Unadjusted Kaplan-Meier estimates were used to
calculate a 2-sided 95% CI for the difference in the pro-
portion of patients with at least one RBC transfusion from
week 5 to EOTP for the Q3W vs QW regimen. Non-inferi-
ority of the Q3W regimen was determined if the upper
limit of the 95% CI for this difference was ≤12.5% (based
on transfusion data from two placebo-controlled darbe-
poetin alfa trials) [8,10]. A sample size of 705 patients was
originally determined to provide 95% power to demon-
strate non-inferiority of the Q3W schedule compared with
the QW schedule in regards to the transfusion rate from
week 5 to EOTP.
Endpoints and statistical methods for the exploratory 
analysis
For the exploratory analysis reported here, data from
patients in the trial were analyzed by their baseline-Hb
category: < 10 g/dL and ≥10 g/dL. Efficacy outcomesBMC Cancer 2009, 9:311 http://www.biomedcentral.com/1471-2407/9/311
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examined in the total population [11], and further sum-
marized here, included the percentage of patients with
RBC transfusions and the Hb profiles over time. In the <
10 g/dL baseline-Hb group, this exploratory analysis also
assessed the incidence of patients who achieved a Hb level
≥10 g/dL and the time to first achievement of a Hb level
≥10 g/dL. Patients in both baseline-Hb groups who had a
baseline Hb value and at least one post-baseline Hb value
were examined for the percentage achieving a Hb level
≥11 g/dL, as well as for how long it took to achieve a Hb
level ≥11 g/dL. There was one patient with Hb > 11 g/dL
at both screening and baseline (ie, protocol violation), as
well as a second patient who had Hb < 11 g/dL at screen-
ing which then rose to 11 g/dL at baseline (screening and
baseline measures could be up to 4 days apart). These two
patients were included in the study and dosed per the pro-
tocol, although they were not included in the analyses of
patients achieving Hb ≥11 g/dL.
Safety endpoints examined in this exploratory analysis
included the incidence of adverse events, the percentage
of patients reaching a Hb level ≥12 g/dL or ≥13 g/dL at any
time on study, and the proportion of patients with a rapid
Hb increase of ≥1 g/dL in a 14-day window or ≥2 g/dL in
a 28-day window.
Statistical analyses were performed using SAS statistical
software (version 8.2, SAS Institute, Cary, NC). Descrip-
tive statistics included frequencies with 95% CIs for cate-
gorical variables and means with standard deviations
(SDs) for continuous variables. Unadjusted Kaplan-Meier
estimates were used to analyze the incidence of transfu-
sions and the proportion of patients achieving a specific
Hb level. Hb concentrations measured within 28 days of
a RBC or whole blood transfusion were excluded from the
analysis. Analyses were not adjusted by stratification fac-
tors used at randomization. Adverse events were grouped
by primary system organ class and by preferred term with
the primary organ system class according to a MedDRA
dictionary (version 7.0).
Results
Patient demographics and disease state
This phase 3 trial included 705 patients at 110 centers in
24 European countries [11]. In the present exploratory
analysis, the 353 patients randomized to the 500 mcg
Q3W darbepoetin arm in the primary study [11] were cat-
egorized into a baseline-Hb group of either < 10 g/dL (176
patients) or ≥10 g/dL (177 patients). The 352 patients ran-
domized to the 2.25 mcg/kg QW darbepoetin arm were
also categorized into a baseline-Hb group of either < 10 g/
dL (175 patients) or ≥10 g/dL (177 patients). Thus, the <
10 g/dL baseline-Hb group contained 351 patients and
the ≥10 g/dL baseline-Hb group contained 354 patients.
The overall mean (SD) baseline Hb level in the < 10 g/dL
baseline-Hb group was 9.05 g/dL (0.71), ranging from 5.9
to 9.9 g/dL, while the mean (SD) in the ≥10 g/dL baseline-
Hb group was 10.48 g/dL (0.30), ranging from 10.0 to
11.8 g/dL (Table 1). Other than the baseline Hb level, the
< 10 g/dL and ≥ 10 g/dL baseline-Hb groups had fairly
similar demographics and baseline characteristics; these
characteristics were also similar across the two darbepoe-
tin dosing schedules (Table 1). Common tumor types in
both the < 10 g/dL and ≥10 g/dL baseline-Hb groups
included large intestine/colon, breast, and non-small cell
lung cancer. Of note, slightly more patients in the ≥10 g/
dL baseline-Hb group had colon cancer. Most patients
analyzed had stage III/IV disease and were < 65 years of
age. In patients receiving Q3W darbepoetin alfa, slightly
more patients in the < 10 g/dL baseline-Hb group had
stage III/IV disease. The majority of patients in this study
had a performance status of 0 or 1 [11].
Transfusions
Unadjusted Kaplan-Meier estimates were used to analyze
the incidence of transfusions from week 5 to EOTP in the
< 10 g/dL and ≥10 g/dL baseline-Hb groups (Table 2). In
a sensitivity analysis, unadjusted Kaplan-Meier estimates
were also used to analyze the incidence of transfusions
from week 1 to EOTP in both baseline-Hb groups. The
results indicated that the incidence of transfusions was
lower in the ≥10 g/dL baseline-Hb group compared with
the < 10 g/dL baseline-Hb group across both dosing
schedules and for both time periods examined (from
week 5 to EOTP and from week 1 to EOTP) (Table 2). In
both baseline-Hb groups, the upper limit of the 95% CI
for the difference in RBC transfusions (for both time peri-
ods examined) between the Q3W and QW groups was less
than the pre-specified non-inferiority margin of 12.5%.
These findings are consistent with results previously
reported from this trial [11] indicating that darbepoetin
alfa administered at 500 mcg Q3W is at least as effective
as darbepoetin alfa administered at 2.25 mcg/kg QW for
reducing transfusion requirements from week 5 to EOTP
and from week 1 to EOTP.
Of the 214 transfusions received by patients, 71% were in
patients with baseline Hb < 10 g/dL. We also examined if
the Hb level preceding the first transfusion was above or
below the Hb threshold of 8 g/dL recommended (but not
mandated) in the protocol (Table 3). For patients with
baseline Hb < 10 g/dL, about half (48%) of first transfu-
sions occurred at or below the protocol-specified thresh-
old of 8 g/dL. For patients with baseline Hb ≥10 g/dL,
38% of the first transfusions occurred at or below the
threshold of 8 g/dL.
Hemoglobin endpoints
In Figure 1, the mean (95% CI) Hb concentrations (g/dL)
over the treatment period in weeks are shown for bothBMC Cancer 2009, 9:311 http://www.biomedcentral.com/1471-2407/9/311
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baseline-Hb groups. By week 5, the ≥10 g/dL baseline-Hb
group, but not the < 10 g/dL baseline-Hb group, achieved
a mean Hb level ≥11 g/dL. The mean (SD) Hb concentra-
tion in the < 10 g/dL baseline-Hb group (Q3W vs QW dos-
ing) was 9.90 g/dL (1.45) vs 9.86 g/dL (1.35) at week 5;
10.04 g/dL (1.37) vs 10.31 g/dL (1.54) at week 7; and
10.46 g/dL (1.57) vs 10.62 g/dL (1.6) at week 15. The
mean (SD) Hb concentration in the ≥10 g/dL baseline-Hb
group (Q3W vs QW dosing) was 11.15 g/dL (1.16) vs
11.02 g/dL (1.36) at week 5; 11.15 g/dL (1.24) vs 11.30 g/
dL (1.39) at week 7; and 11.38 g/dL (1.02) vs 11.30 g/dL
(1.30) at week 15. In both baseline-Hb groups, the mean
Hb level remained under 12 g/dL throughout the entire
treatment period (Figure 1).
We determined time to reach two Hb levels (10 g/dL and
11 g/dL) because of differing recommendations regarding
ESA treatment present in the US and EU product informa-
tion [16-19]. For patients in the < 10 g/dL baseline-Hb
group, the unadjusted Kaplan-Meier estimated percentage
(95% CI) of patients who achieved a Hb level ≥10 g/dL
(Q3W vs QW dosing) was 43% (36 to 51) vs 48% (40 to
55) by week 5, 59% (51 to 66) vs 56% (48 to 64) by week
7, and 78% (70 to 84) vs 83% (76 to 89) by EOTP (Figure
2). The unadjusted Kaplan-Meier estimated percentage
(95% CI) of patients in the < 10 g/dL baseline-Hb group
who achieved a Hb level ≥10 g/dL (Q3W vs QW dosing)
from week 5 to EOTP was 75% (68 to 82) vs 82% (75 to
89) and 78% (71 to 85) vs 83% (77 to 90) from week 1 to
Table 1: Patient demographics and baseline disease state
Baseline Hemoglobin < 10 g/dL Baseline Hemoglobin ≥10 g/dL
Darbepoetin alfa 
500 mcg Q3W
N = 176
Darbepoetin alfa 
2.25 mcg/kg QW
N = 175
Total
N = 351
Darbepoetin alfa 
500 mcg Q3W
N = 177
Darbepoetin alfa 
2.25 mcg/kg QW
N = 177
Total
N = 354
Sex, n (%)
Female 93 (53) 97 (55) 190 (54) 93 (53) 100 (56) 193 (55)
Age, years
Median 
(Min, Max)
59 (20, 86) 61 (20, 83) 60 (20, 86) 61 (20, 85) 60 (21, 84) 60.5 (20, 85)
≥65, n (%) 59 (34) 65 (37) 124 (35) 65 (37) 65 (37) 130 (37)
≥75, n (%) 15 (9) 14 (8) 29 (8) 19 (11) 12 (7) 31 (9)
Tumor type, n (%)
Large Intestine/
Colon
30 (17) 16 (9) 46 (13) 35 (20) 35 (20) 70 (20)
Breast 23 (13) 27 (15) 50 (14) 34 (19) 28 (16) 62 (18)
NSCLC 17 (10) 15 (9) 32 (9) 17 (10) 17 (10) 34 (10)
Disease stage at 
diagnosis, n (%)
I 13 (7) 10 (6) 23 (7) 15 (8) 8 (5) 23 (6)
II 25 (14) 38 (22) 63 (18) 40 (23) 37 (21) 77 (22)
III 53 (30) 49 (28) 102 (29) 42 (24) 44 (25) 86 (24)
IV 74 (42) 62 (35) 136 (39) 59 (33) 71 (40) 130 (37)
Other/Missing or 
Unknown
11 (6) 16 (9) 27 (8) 21 (12) 17 (10) 38 (11)
Prior 
chemotherapy, n 
(%)
169 (96) 153 (87) 322 (92) 162 (92) 154 (87) 316 (89)
Prior platinum 
chemotherapy, n 
(%)
68 (39) 59 (34) 127 (36) 59 (33) 63 (36) 122 (34)
Prior radiotherapy, 
n (%)
60 (34) 47 (27) 107 (30) 61 (34) 56 (32) 117 (33)
Prior erythropoietic 
therapy, n (%)a
21 (12) 21 (12) 42 (12) 18 (10) 13 (7) 31 (9)
Baseline 
hemoglobin, g/dL
Mean (SD) 9.01 (0.78) 9.09 (0.64) 9.05 (0.71) 10.50 (0.29) 10.46 (0.30) 10.48 (0.30)
Median 
(Min, Max)
9.20 (5.9, 9.9) 9.20 (6.8, 9.9) 9.20 (5.9, 9.9) 10.50 (10.0, 10.9) 10.50 (10.0, 11.8) 10.50 (10.0, 11.8)
Q3W = every three weeks; QW = weekly; Min = minimum; Max = maximum; NSCLC = non-small cell lung cancer; SD = standard deviation
aPrior erythropoietic agents were not administered within 4 weeks of study day 1.BMC Cancer 2009, 9:311 http://www.biomedcentral.com/1471-2407/9/311
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EOTP. The Kaplan-Meier median (95% CI) time to
achieve a ≥10 g/dL Hb level (Q3W vs QW dosing) was 8
weeks (6 to 9) vs 7 weeks (6 to 9) from week 5 to EOTP
and 6 weeks (4 to 7) vs 6 weeks (5 to 8) from week 1 to
EOTP (Figure 2). Figure 3 shows the time for patients in
both baseline-Hb groups to achieve a Hb level ≥11 g/dL.
The unadjusted Kaplan-Meier percentage (95% CI) of
patients (Q3W vs QW dosing) who achieved a Hb level
≥11 g/dL was 54% (46 to 62) vs 57% (49 to 65) in < 10 g/
dL baseline-Hb group and 90% (85 to 94) vs 85% (79 to
90) in the ≥10 g/dL baseline-Hb group.
Drug exposure and safety endpoints
The present exploratory analysis of the < 10 g/dL and ≥10
g/dL baseline-Hb groups examined drug exposure and
safety outcomes. Table 4 summarizes drug exposure and
the percentages of patients in both baseline-Hb groups
who: 1) reached the Hb threshold of ≥12 g/dL or ≥13 g/
dL, 2) had a dose withheld due to achievement of Hb > 13
g/dL, 3) had a rapid rate of Hb rise (≥1-g/dL Hb rise over
a 14-day window or a ≥2-g/dL Hb rise over a 28-day win-
dow), or 4) had a dose reduction due to a rapid Hb rise
(≥1-g/dL Hb rise in a 14-day window in the absence of a
transfusion during the previous 14 days). Both the pro-
portion of those who achieved a threshold Hb of ≥12 or
≥13 g/dL and the proportion of those who experienced a
rapid rise in Hb were higher in the ≥10 g/dL baseline-Hb
group.
The incidence of any adverse events (not necessarily treat-
ment related) in the < 10 g/dL baseline-Hb group was
91% in both the Q3W and QW dosing groups. The inci-
dence of any adverse event in the ≥10 g/dL baseline-Hb
group was 85% in the Q3W dosing group and 88% in the
QW dosing group. The most common adverse events in
both baseline-Hb groups were nausea, vomiting, pyrexia,
fatigue, and diarrhea. The incidence of serious adverse
events (Q3W vs QW dosing) was 48% vs 42% in the < 10
g/dL baseline-Hb group and 31% vs 34% in the ≥10 g/dL
baseline-Hb group. The most common serious adverse
events in the < 10 g/dL baseline-Hb group (Q3W vs QW
dosing) were pyrexia (6% of patients vs 6% of patients),
Table 2: Incidence of transfusions
Baseline Hemoglobin < 10 g/dL Baseline Hemoglobin ≥10 g/dL
Darbepoetin 
alfa 500 mcg 
Q3W
N = 176
Darbepoetin alfa 
2.25 mcg/kg 
QW
N = 175
Difference
(Q3W-QW)
Darbepoetin 
alfa 500 mcg 
Q3W
N = 177
Darbepoetin alfa 
2.25 mcg/kg 
QW
N = 177
Difference
(Q3W-QW)
Week 5 to EOTP 
K-M percent (95% 
CI) [N]
36 (28 to 43) [164] 41 (33 to 49) [167] -5.1 (-16.1 to 5.9) 14 (7 to 20) [171] 21 (14 to 29) [170] -7.3(-17.3 to 2.8)
Week 1 to EOTP 
K-M percent 
(95% CI)
44 (37 to 52) 47 (39 to 54) -2.3 (-13.2 to 8.6) 14 (8 to 21) 26 (18 to 33) -11.3 
(-21.4 to -1.2)
Q3W = every three weeks; QW = weekly; EOTP = end of the treatment period (defined as the earlier of day 109 or end of study); K-M = Kaplan-
Meier
Table 3: Number of first transfusions occurring at hemoglobin ≤8 g/dL or > 8 g/dL
Baseline Hemoglobin < 10 g/dL Baseline Hemoglobin ≥10 g/dL
Darbepoetin alfa 
500 mcg Q3W
Darbepoetin alfa 
2.25 mcg/kg QW
Darbepoetin alfa 
500 mcg Q3W
Darbepoetin alfa 
2.25 mcg/kg QW
Firsta transfusion during 
week 5 to EOTP
Hb ≤8 g/dL, n (%) 30 (56) 29 (46) 12 (55) 12 (39)
Hb > 8 g/dL, n (%) 24 (44) 34 (54) 10 (45) 19 (61)
Firsta transfusion during 
week 1 to EOTP
Hb ≤8 g/dL, n (%) 42 (58) 30 (38) 9 (39) 14 (35)
Hb > 8 g/dL, n (%) 30 (41) 48 (62) 14 (61) 24 (60)
Hb missing, n (%) 1 (1) 0 (0) 0 (0) 2 (5)
Q3W = every three weeks; QW = weekly; EOTP = end of the treatment period (defined as the earlier of day 109 or end of study); Hb = 
hemoglobin; n = number of transfusion events. Note that as data described are for first transfusion only, n also equals the number of patients with 
at least one transfusion.
aThe closest hemoglobin value on the day of transfusion or within 7 days prior was used.BMC Cancer 2009, 9:311 http://www.biomedcentral.com/1471-2407/9/311
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febrile neutropenia (6% of patients vs 5% of patients),
and anemia (3% of patients vs 5% of patients). The most
common serious adverse events in the ≥10 g/dL baseline-
Hb group (Q3W vs QW dosing) were pyrexia (4% of
patients vs 5% of patients), deep-vein thrombosis (3% of
patients vs 4% of patients), and anemia (2% of patients in
each dosing group). Serious treatment-related adverse
events (Q3W vs QW dosing) occurred in 3% vs 2% of
patients in the < 10 g/dL baseline-Hb group and in 3% vs
4% of patients in the ≥10 g/dL baseline-Hb group. No
anti-darbepoetin alfa antibodies were detected in any
patients who received darbepoetin alfa in either baseline-
Hb group [11].
In the < 10 g/dL and ≥10 g/dL baseline-Hb groups, safety
analyses also examined the incidence of deaths on study,
disease progression, and adverse events of historical inter-
est, which include cardiovascular and thromboembolic
events since there is a known risk of increased embolism/
thrombosis with ESA use [6,30] (Table 5). Deaths over the
whole study occurred in 11% of Q3W patients and in 15%
of QW patients [11]; causes of death included infections,
cardiac complications, and respiratory complications.
Deaths were more frequent in the < 10 g/dL baseline-Hb
group (Table 5). The incidences of most cardiovascular
and thromboembolic events were similar in the two base-
line-Hb groups except for a slightly increased incidence of
arrhythmias in patients in the ≥10 g/dL baseline-Hb
group who received QW darbepoetin alfa; there was also
a slightly higher incidence of embolism/thrombosis
events in the ≥10 g/dL baseline-Hb group compared with
the < 10 g/dL baseline-Hb group.
Of a total of 73 thromboembolic events reported during
the study, 64% (47) occurred in patients with baseline Hb
≥10 g/dL. The most common thromboembolic events
were: deep venous thrombosis (36%), general phlebitis/
thrombosis (36%), and pulmonary embolism (18%).
Thirty of the 73 events resulted in hospitalization, includ-
ing 19 in patients with baseline Hb ≥10 g/dL. Twelve of
these 19 hospitalizations occurred in patients on QW dos-
ing, as compared with 7 on Q3W dosing. Of the 19 hospi-
talizations in patients with baseline Hb ≥10 g/dL, 10 were
due to deep venous thrombosis and 6 to pulmonary
embolism, with both events occurring with both dosing
schedules. Two thromboembolic-related fatalities
occurred, both in patients with pulmonary embolism.
Hemoglobin profile over the treatment period Figure 1
Hemoglobin profile over the treatment period. The 
mean hemoglobin (Hb) concentration (g/dL) is shown over 
time in weeks. The treatment period lasted through the ear-
lier of day 109 or end of study. Error bars represent the 95% 
confidence intervals. The dotted, black horizontal line marks 
the 11 g/dL Hb level on the Y axis, and the dotted, black ver-
tical line marks week 5 on the X axis. A. Patients with a base-
line Hb level < 10 g/dL. B. Patients with a baseline Hb level 
≥10 g/dL
174 Q3W n= 149 132 120 114 121 107 103 111 97 94 97 94 88 82 69
172 QW   n= 152 141 131 126 122 114 115 108 108 97 93 90 83 80 56
 QW   = Darbepoetin alfa 2.25 mcg/kg QW
 Q3W = Darbepoetin alfa 500 mcg Q3W
M
e
a
n
 
H
b
 
C
o
n
c
e
n
t
r
a
t
i
o
n
 
(
g
/
d
L
)
8.5
9.0
9.5
10.0
10.5
11.0
11.5
12.0
Study Week
B a s e l i n e 23456789 1 0 1 1 1 2 1 3 1 4 1 5 1 6
174 Q3W n= 163 157 152 154 153 151 147 141 141 143 132 126 131 116 92
174 QW   n= 163 155 141 143 138 140 139 137 131 122 111 112 100 99 71
 QW   = Darbepoetin alfa 2.25 mcg/kg QW
 Q3W = Darbepoetin alfa 500 mcg Q3W
M
e
a
n
 
H
b
 
C
o
n
c
e
n
t
r
a
t
i
o
n
 
(
g
/
d
L
)
8.5
9.0
9.5
10.0
10.5
11.0
11.5
12.0
Study Week
B a s e l i n e 23456789 1 0 1 1 1 2 1 3 1 4 1 5 1 6
A. Patients with a baseline Hb < 10 g/dL
B. Patients with a baseline Hb ≥ 10 g/dL
Time to hemoglobin concentration ≥10 g/dL for patients with  baseline hemoglobin < 10 g/dL Figure 2
Time to hemoglobin concentration ≥10 g/dL for 
patients with baseline hemoglobin < 10 g/dL. Hemo-
globin (Hb) measurements within 28 days of a red blood cell 
transfusion or whole blood transfusion were excluded. 
Patients not achieving a Hb level ≥10 g/dL between day 1 and 
end of the treatment period (EOTP, earlier of day 109 or 
end of study) were censored at their last Hb measurement 
prior to EOTP.
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One of these patients had baseline Hb < 10 g/dL (Q3W
dosing) and one had baseline Hb ≥10 g/dL (QW dosing).
Discussion
The recent changes made globally to the ESA product
information may affect how anemia is treated in cancer
patients in both the EU and the US. The EU ESA product
information states that ESA therapy be initiated in
patients with baseline Hb ≤10 g/dL and that the target Hb
range should be 10 to 12 g/dL [16,17]. In addition, the EU
ESA product information also states that the decision to
administer ESAs should be based on a benefit-risk assess-
ment made with the participation of the individual
patient that takes into account the specific clinical context
(eg, the type of cancer and disease stage, the degree of ane-
mia, life expectancy, and the environment in which the
patient is being treated) and patient preference; in some
clinical situations, blood transfusion should be the pre-
ferred treatment for anemia management in cancer
patients [16,17]. The US ESA product information [18,19]
states that ESAs be used to maintain the lowest possible
Hb level while still avoiding transfusions. This exploratory
analysis examined how the baseline Hb level (< 10 g/dL vs
≥10 g/dL) at which darbepoetin alfa administration was
initiated in CIA patients affected response to darbepoetin
alfa therapy. Overall, the results from this exploratory
analysis indicated that darbepoetin alfa therapy corrected
anemia in both baseline-Hb groups (though correction
was faster in the ≥10 g/dL baseline-Hb group), irrespective
of the dosing schedule (Q3W or QW). In addition, the
incidence of most adverse events was generally similar
between the two baseline-Hb groups.
In both baseline-Hb groups, Hb levels could be effectively
raised with either the Q3W or QW darbepoetin alfa
administration schedule to achieve Hb levels between 10
to 12 g/dL. In this analysis, initiating darbepoetin alfa
therapy in patients with baseline Hb ≥10 g/dL (in both the
Q3W and QW schedules) resulted in fewer transfusions
compared with patients with a baseline Hb < 10 g/dL. Fur-
ther, patients with ≥10 g/dL baseline Hb were more likely
to achieve Hb levels between 11 and 12 g/dL (while still
maintaining mean Hb levels below 12 g/dL) and to do so
more quickly compared with patients with baseline Hb <
10 g/dL. However, since the original study was not
designed to compare results in patients with baseline Hb
< 10 g/dL with those seen in patients with a baseline Hb
≥10 g/dL, additional studies are needed to examine this
point.
It should be noted that among patients with baseline Hb
≥10 g/dL, more achieved Hb levels ≥12 g/dL or ≥13 g/dL
and more experienced a rapid rise in Hb than did patients
with baseline Hb < 10 g/dL. Rises in Hb of that degree
have also been observed in patients in placebo groups in
controlled trials of darbepoetin alfa for CIA [8,10], which
makes interpretation difficult. Additionally, a recent
meta-analysis of six placebo-controlled darbepoetin alfa
trials found no increased risk of death or disease progres-
sion in ESA-treated patients achieving higher Hb levels
(>12 g/dL or 13 g/dL) or with a rapid rise in Hb [31].
However, it is possible that those patients who were more
responsive to ESAs were generally healthier, as ESA
response and improved survival could both reflect better
heath status. Further, in a recent larger meta-analysis (53
trials), target Hb was not found to be associated with
changes in mortality [29].
A particular concern is that in patients who start Q3W
dosing, Hb levels will undergo transient excursions into
concentrations that exceed the Hb level needed to avoid a
Time to a hemoglobin concentration ≥11 g/dL Figure 3
Time to a hemoglobin concentration ≥11 g/dL. Hemo-
globin (Hb) measurements within 28 days of a red blood cell 
transfusion or whole blood transfusion were excluded. 
Patients not achieving a Hb level ≥11 g/dL between day 1 and 
end of the treatment period (EOTP, earlier of day 109 or 
end of study) were censored at their last Hb measurement 
prior to EOTP. Two patients in the ≥10 g/dL baseline-Hb 
group who had a baseline Hb level ≥11 g/dL were excluded 
from the analysis. A. Patients with a baseline Hb level < 10 g/
dL. B. Patients with a baseline Hb level ≥10 g/dL.
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transfusion or exceed the Hb range of 10 to 12 g/dL. In
this study, the mean Hb concentrations remained below
12 g/dL for both baseline-Hb groups throughout the
study, irrespective of the dosing schedule (Q3W or QW).
With the dosing rules used in this study, the percentage of
patients within each baseline-Hb group who reached a Hb
concentration of ≥12 g/dL or ≥13 g/dL was comparable for
both the Q3W and QW dosing groups, allaying concerns
about Hb concentrations exceeding recommended levels
with the Q3W schedule. Dose modifications in this study
resulted predominantly from the dose reduction rule for
patients with a Hb rise of ≥1 g/dL in a 14-day period. In
the EU, the currently approved product information for
darbepoetin alfa indicates similar dose reduction and
stopping rules as those used in this trial (darbepoetin alfa
administration was withheld in this trial at a Hb concen-
tration > 13 g/dL and was reinstated at 60% of the previ-
ous dose after Hb levels decreased to 12 g/dL or less).
Using titration of ESA doses may be the best method to
achieve the lowest Hb dose to avoid transfusions or to
maintain Hb levels in a range of 10 to 12 g/dL.
Though the safety profiles were generally similar in the
two baseline-Hb groups, more deaths occurred in the < 10
g/dL baseline-Hb group. One possibility is that the
patients with a lower baseline Hb level may have had a
worse prognosis. Of interest, though the < 10 g/dL base-
line-Hb group had more deaths, fewer thromboembolic
events occurred in this group compared with the ≥10 g/dL
baseline-Hb group.
An inherent limitation of this analysis was that it was not
pre-specified (ie, it was exploratory). The original study
was designed as a noninferiority efficacy study, and thus
was not prospectively designed to assess safety. In addi-
tion, as with any post hoc analysis, performing multiple
analyses can increase chance fluctuations in the outcomes.
Therefore, these results cannot be considered as robust as
those from a pre-specified analysis plan. Additional limi-
tations arise from the original study design and heteroge-
neous patient population, both of which could confound
results. Specifically, as this was a noninferiority study,
there was no comparator placebo arm. Likewise, as this
study was conducted at 110 medical centers in 24 coun-
tries, there could well be variations in transfusion prac-
tices from site to site or country to country. These
differences were allowed by the protocol, which recom-
mended, but did not mandate, transfusions for patients
with Hb level ≤8 g/dL. For the patient population, other
than having at least 12 additional weeks of planned cyto-
Table 4: Incidence of hemoglobin levels ≥12 g/dL or ≥13 g/dL or rapid hemoglobin rises
Baseline Hemoglobin < 10 g/dL Baseline Hemoglobin ≥10 g/dL
Darbepoetin alfa 500 
mcg Q3W
N = 176
Darbepoetin alfa 2.25 
mcg/kg QW
N = 175
Darbepoetin alfa 500 
mcg Q3W
N = 177
Darbepoetin alfa 2.25 
mcg/kg QW
N = 177
Mean (SD) average weekly 
darbepoetin alfa dose, mcg/
weeka
134 (36) 115 (41) 125 (34) 112 (43)
Hemoglobin threshold of 
≥12 g/dL achieved at any 
time during the study, n 
(%)b
44 (31) 49 (34) 109 (66) 99 (63)
Hemoglobin threshold of 
≥13 g/dL achieved at any 
time during the study, n 
(%)b
20 (11) 24 (14) 56 (32) 60 (34)
Dose withheld due to 
achievement of > 13 g/dL 
hemoglobin, n (%)
4 (2) 22 (13) 12 (7) 57 (32)
Rapid rise in hemoglobin, n 
(%)
≥1 g/dL in 14 days 99 (56) 103 (59) 133 (75) 119 (67)
≥2 g/dL in 28 days 48 (27) 54 (31) 70 (40) 64 (36)
Dose reduction due to 
rapid hemoglobin 
increasec, % (95% CI)
57 (49 to 64) 69 (61 to 75) 75 (67 to 81) 69 (62 to 76)
Q3W = every three weeks; QW = weekly
aExcluding withheld or missed doses.
bHemoglobin measurements within 28 days of a RBC transfusion or whole blood transfusion were excluded.
cA rapid hemoglobin increase sufficient to trigger dose reduction was defined as ≥1 g/dL hemoglobin rise in a 14-day window in the absence of a 
transfusion during the previous 14 days.BMC Cancer 2009, 9:311 http://www.biomedcentral.com/1471-2407/9/311
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toxic chemotherapy, there were no limitations regarding
chemotherapy type. Patients also had different stages of
disease and a variety of tumor types, including lung,
breast, colon, and hematologic. Patient populations with
baseline Hb < 10 g/dL or ≥10 g/dL appeared generally
well-balanced regarding stage and tumor type (Table 1);
however, that does not rule out subtle differences that
could affect interpretation. Lastly, the proportion of
patients in each group who died could be a possible con-
founding factor. To determine what role this last factor
might have, we examined survival curves and performed
additional analyses using death as a competing risk (data
not shown, methodology described in [32]). These analy-
ses indicated that death or timing of death did not sub-
stantially affect the data.
Taken together, the data from this exploratory analysis
indicate that patients with baseline Hb < 10 g/dL and ≥10
g/dL may benefit from ESA therapy. However, given our
evolving understanding of possible long-term safety
issues related to ESA use, including the effect of the Hb
level at ESA initiation as well as target and/or achieved Hb
levels, these results should be interpreted with caution.
Ongoing long-term safety studies are expected to provide
more clarity on these and other issues. Therefore, while
these initial results contribute to the ongoing discussion
of how to best use ESAs in patients with CIA, there are a
variety of limitations of this exploratory analysis. Addi-
tional prospective studies that examine outcomes in
patients treated with ESAs according to the current ESA
product information will be of interest to clinical practice.
Conclusion
Recent changes have been made globally to the ESA prod-
uct information, including changes in the recommended
baseline Hb level at which ESA therapy should be initiated
in CIA patients. To examine how these changes may affect
patient care, this exploratory analysis retrospectively
examined outcomes in darbepoetin alfa-treated CIA
patients who were categorized into baseline-Hb strata of <
10 g/dL or ≥10 g/dL at initiation of ESA therapy. In this
analysis, darbepoetin alfa administered 500 mcg Q3W or
Table 5: Incidence of adverse events of historical interest, death on-study, and disease progressiona
Baseline Hemoglobin < 10 g/dL Baseline Hemoglobin ≥10 g/dL
Darbepoetin alfa 500 
mcg Q3W
N = 176
Darbepoetin alfa 2.25 
mcg/kg QW
N = 175
Darbepoetin alfa 500 
mcg Q3W
N = 177
Darbepoetin alfa 2.25 
mcg/kg QW
N = 177
Adverse events of 
historical interest, death 
on-study, and disease 
progression, n (%)
84 (48) 80 (46) 67 (38) 75 (42)
On-study deaths, n (%) 24 (14) 32 (18) 14 (8) 20 (11)
Disease progression, n (%) 42 (24) 37 (21) 29 (16) 36 (20)
Cardiovascular and 
thromboembolic events, n 
(%)
22 (12) 27 (15) 33 (19) 34 (19)
Arrhythmias 7 (4) 7 (4) 9 (5) 13 (7)
Cerebrovascular 
accident
0 (0) 2 (1) 0 (0) 1 (0.6)
Congestive heart failure 5 (3) 7 (4) 4 (2) 6 (3)
Myocardial infarction/
Coronary artery 
disorders
2 (1) 3 (2) 3 (2) 0 (0)
Embolism/Thrombosis 11 (6) 11 (6) 19 (11) 17 (10)
Seizure, n (%) 1 (0.6) 0 (0) 0 (0) 1 (0.6)
Hypertension, n (%) 6 (3) 7 (4) 2 (1) 6 (3)
Pure red blood cell aplasia, 
n (%)
0 (0) 0 (0) 0 (0) 0 (0)
Immune system disorders, 
n (%)
0 (0) 1 (0.6) 1 (0.6) 2 (1)
Neoplasms benign, 
malignant, or unspecified 
(includes cysts/polyps), n 
(%)
44 (25) 33 (19) 14 (8) 26 (15)
Q3W = every three weeks; QW = weekly
aIncludes all events within 28 days of the last dose of study drug (except serious adverse events, which were reported at any time after the first 
dose of study drug).BMC Cancer 2009, 9:311 http://www.biomedcentral.com/1471-2407/9/311
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2.25 mcg/kg QW raised Hb levels in both baseline-Hb
groups while still maintaining mean Hb levels below 12
g/dL as recommended by the EU ESA product informa-
tion. However, patients with a baseline Hb level ≥10 g/dL
had fewer transfusions and faster anemia correction com-
pared with patients in the < 10 g/dL baseline-Hb group.
Safety profiles were generally similar in both baseline-Hb
groups except that the < 10 g/dL baseline-Hb group had a
slightly higher incidence of deaths while the ≥10 g/dL
baseline-Hb group had a slightly higher incidence of
thromboembolic events and a higher incidence of
patients reaching a Hb level ≥13 g/dL. Since this was a ret-
rospective analysis, additional studies are warranted to
examine how baseline Hb levels at initiation of ESA ther-
apy affect hematological responses and safety outcomes.
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